Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Acute Pain, Molar, Molar, Third, Surgery, Oral
Interventions: LY4515100, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Type 1 Diabetes Mellitus, Diabetes
Interventions: REMD-477, Placebo Comparator; Biological
Lead sponsor: REMD Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: San Diego, California • St Louis, Missouri

Conditions: Alveolar Bone Loss, Periodontal Diseases
Interventions: beta-tricalcium phosphate alone, GFeBGS 0.1%, GFeBGS 0.3%, GFeBGS 0.4%; Device
Lead sponsor: Sunstar Americas; Industry
Eligibility: 25 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Fullerton, California • Aurora, Colorado + 3 more

Conditions: Motivation
Interventions: Study Product, THC Product, Placebo; Behavioral
Lead sponsor: Phylos Bioscience, Inc.; Industry
Eligibility: 21 Years to 100 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric
Interventions: Phenoptin; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more

Conditions: Alcohol Misuse, Sexual Assault
Interventions: Positive Change© for Sailors; Behavioral
Lead sponsor: Naval Health Research Center; Federal
Eligibility: 18 Years to 24 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Tempe, Arizona • San Diego, California • Atlanta, Georgia + 1 more

Conditions: Postoperative Pain
Interventions: Liposomal bupivacaine, Standard of care; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Shoulder Dystocia
Interventions: Yaari Extractor; Device
Lead sponsor: FetalEase Ltd.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Miami, Florida • Idaho Falls, Idaho • Winston-Salem, North Carolina + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: LY3532226, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Thyroid Eye Disease
Interventions: AMG 732, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more

Conditions: Healthy Subjects
Interventions: ASP5354, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Autism Spectrum Disorder
Interventions: Autism ALERT, Screening Intervention; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 12 Months to 54 Months
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Cognitive Impairment, no Dementia (CIND)
Interventions: Aerobic Exercise, DASH diet, Health education control; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Severe Sepsis
Interventions: BMS-986189, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Gastroesophageal Reflux
Interventions: Dexlansoprazole MR QD; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 52
States / cities: Hueytown, Alabama • Chandler, Arizona • Sierra Vista, Arizona + 49 more

Conditions: Type 1 Diabetes
Interventions: Insulin, Asp(B28)-, Glucagon, Placebo; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anterior Acute Myocardial Infarction (AMI)
Interventions: Supersaturated O2 Therapy of the Therox Downstream System®, PCI alone; Device · Procedure
Lead sponsor: TherOx; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Charleston, West Virginia • Huntington, West Virginia

Conditions: Headache
Interventions: Superficial Dry Needling, Non-thrust Mobilizations only; Other
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Lomecel-B medicinal signaling cells; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: Up to 12 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Anorexia Nervosa/Bulimia, Anorexia in Adolescence, Anorexia Nervosa, Atypical, Anorexia Nervosa, Binge Eating/Purging Type, Purging (Eating Disorders), Impulsive Behavior, Eating Disorders, Bulimia Nervosa, Eating Disorders in Adolescence
Interventions: Naltrexone Hydrochloride, Control; Drug · Other
Lead sponsor: Rosemary Claire Roden; Other
Eligibility: 13 Years to 25 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Focus: Assess Post Infusion Viability of S303 RBCs
Interventions: S303 Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells (RBCs); Biological
Lead sponsor: Cerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Dexmethylphenidate; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

A Direct-to-Consumer Study Investigating the Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite in Healthy Adults

Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency

Positive Change for Sailors

Optimizing Recovery in Abdominoplasty

Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

Autism Access Link for Early Referral and Treatment

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System

Superficial Dry Needling for Cervicogenic Headache

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Oral Naltrexone In Pediatric Eating Disorders

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells

In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)